<code id='41F07214B6'></code><style id='41F07214B6'></style>
    • <acronym id='41F07214B6'></acronym>
      <center id='41F07214B6'><center id='41F07214B6'><tfoot id='41F07214B6'></tfoot></center><abbr id='41F07214B6'><dir id='41F07214B6'><tfoot id='41F07214B6'></tfoot><noframes id='41F07214B6'>

    • <optgroup id='41F07214B6'><strike id='41F07214B6'><sup id='41F07214B6'></sup></strike><code id='41F07214B6'></code></optgroup>
        1. <b id='41F07214B6'><label id='41F07214B6'><select id='41F07214B6'><dt id='41F07214B6'><span id='41F07214B6'></span></dt></select></label></b><u id='41F07214B6'></u>
          <i id='41F07214B6'><strike id='41F07214B6'><tt id='41F07214B6'><pre id='41F07214B6'></pre></tt></strike></i>

          Home / fashion / comprehensive

          comprehensive


          comprehensive

          author:entertainment    Page View:43631

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In